[
  {
    "ts": null,
    "headline": "These 4 Dividend Stocks Are Money-Printing Machines",
    "summary": "These companies generate lots of cash to pass on to shareholders.",
    "url": "https://finnhub.io/api/news?id=c3a5069e0d7b1349e053bf5d8888838901733cb0913ef942a054b4926d62a958",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756667400,
      "headline": "These 4 Dividend Stocks Are Money-Printing Machines",
      "id": 136596097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "These companies generate lots of cash to pass on to shareholders.",
      "url": "https://finnhub.io/api/news?id=c3a5069e0d7b1349e053bf5d8888838901733cb0913ef942a054b4926d62a958"
    }
  },
  {
    "ts": null,
    "headline": "New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump",
    "summary": "Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3% (95% CI: 0.54 to 0.92)1. When compared to the control arm at 10 years, Impella CP patient",
    "url": "https://finnhub.io/api/news?id=1ce5cb41ea0719eac8ac8112639e046e919fb1e90b1a4734855d550b872ce505",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756660500,
      "headline": "New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump",
      "id": 136596106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3% (95% CI: 0.54 to 0.92)1. When compared to the control arm at 10 years, Impella CP patient",
      "url": "https://finnhub.io/api/news?id=1ce5cb41ea0719eac8ac8112639e046e919fb1e90b1a4734855d550b872ce505"
    }
  },
  {
    "ts": null,
    "headline": "Large-cap biotech is a sector to watch for investors: Analysts",
    "summary": "Large-cap biotechs are a potential new asset class as China and D.C. pressure Big Pharma to invest elsewhere.",
    "url": "https://finnhub.io/api/news?id=0662f07a31d05278cb660cdf2621d1dc4a73cf29cd67af073f9e563f506cfd9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756644000,
      "headline": "Large-cap biotech is a sector to watch for investors: Analysts",
      "id": 136588775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Large-cap biotechs are a potential new asset class as China and D.C. pressure Big Pharma to invest elsewhere.",
      "url": "https://finnhub.io/api/news?id=0662f07a31d05278cb660cdf2621d1dc4a73cf29cd67af073f9e563f506cfd9c"
    }
  }
]